POST-TEST

Oncology Today with Dr Neil Love: Current and Future Role of Menin Inhibitors for Patients with Acute Myeloid Leukemia

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. **Which of the following side effects is more commonly associated with ziftomenib than with other menin inhibitors?**
   a. QTc prolongation
   b. Myelosuppression
   c. Differentiation syndrome
   d. Pruritus

2. **Which of the following best describes the overall response rate (ORR) observed with ziftomenib in combination with 7 + 3 chemotherapy for appropriately selected patients with newly diagnosed acute myeloid leukemia (AML) in a Phase II trial?**
   a. 15%
   b. 40%
   c. 70%
   d. Greater than 90%

3. **Menin inhibitors have demonstrated efficacy in AML with which of the following alterations?**
   a. NPM1 mutations
   b. KMT2A rearrangements
   c. Both NPM1 mutations and KMT2A rearrangements
   d. Neither NPM1 mutations nor KMT2A rearrangements

4. **KMT2A rearrangements are most commonly observed in which of the following patient populations?**
   a. Patients with acute promyelocytic leukemia
   b. Patients with therapy-related AML
   c. Patients over age 80 with AML
   d. Patients with acute erythroid leukemia

5. **In the Phase Ib Beat AML trial, revumenib resulted in an ORR of approximately 88% in appropriately selected patients with AML when administered as front-line therapy in combination with which of the following agents/regimens?**
   a. Standard 7 + 3
   b. Venetoclax and azacitidine
   c. CPX-351
   d. Gilteritinib